Want to see TSE:HEAL full AI Analyst Report?
Top Page
Restart Life Sciences
(HEAL)
Select Model
Select Model
Rating:40Underperform
Price Target:
C$0.07
▼(-4.29% Downside)
Action:Downgraded
Date:08/07/26
The score is primarily driven by weak financial performance (no recurring revenue, persistent losses, and ongoing cash burn), reinforced by bearish technical indicators (below key moving averages, negative MACD, very low RSI). Valuation provides limited support because negative earnings make P/E less meaningful and no dividend yield is available.
Positive Factors
Improved 2025 equity position
The return to positive equity in 2025 indicates a meaningful improvement from the company’s recent balance-sheet weakness. Although stability has not been demonstrated over a long period, this change may improve financing flexibility and provide a stronger base for pursuing future operations.
Negative Factors
No recurring revenue base
A five-year absence of reported revenue shows that the company has not established a recurring commercial base to support operations. Without demonstrated sales, growth depends on developing and monetizing activities, making future earnings power uncertain and limiting internal funding capacity.
Read all positive and negative factors
Positive Factors
Negative Factors
Improved 2025 equity position
The return to positive equity in 2025 indicates a meaningful improvement from the company’s recent balance-sheet weakness. Although stability has not been demonstrated over a long period, this change may improve financing flexibility and provide a stronger base for pursuing future operations.
Read all positive factors
Restart Life Sciences (HEAL) vs. iShares MSCI Canada ETF (EWC)
Market Cap
C$4.58M
Dividend YieldN/A
Average Volume (3M)21.82K
Price to Earnings (P/E)―
Beta (1Y)0.63
Revenue GrowthN/A
EPS Growth-450.88%
CountryCA
Employees3
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.03
Shares Outstanding62,506,542
10 Day Avg. Volume600
30 Day Avg. Volume21,819
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)3.29
Price to Sales (P/S)0.00
P/FCF Ratio-5.91
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Restart Life Sciences Business Overview & Revenue Model
Company Description
Operating internationally through its various subsidiaries, Restart Life Sciences Corp. functions as a biotechnology firm. Its core endeavors include the creation of natural therapeutic remedies tailored for individuals with autism spectrum disord...
How the Company Makes Money
null...
Restart Life Sciences Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
38
Negative
Cash Flow
20
Very Negative
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 465.71K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -815.18K | 0.00 | 0.00 | 25.41K | -3.79K | -5.00K |
| EBITDA | -1.52M | -1.34M | -656.20K | -1.20M | -1.84M | -2.68M |
| Net Income | -1.50M | -1.39M | 224.75K | -1.22M | -3.76M | -2.68M |
Balance Sheet | ||||||
| Total Assets | 1.90M | 1.77M | 190.40K | 31.06K | 296.79K | 881.16K |
| Cash, Cash Equivalents and Short-Term Investments | 762.36K | 1.65M | 169.95K | 8.09K | 266.52K | 218.73K |
| Total Debt | 348.35K | 245.36K | 79.88K | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 578.90K | 480.21K | 489.47K | 841.66K | 255.44K | 422.06K |
| Stockholders Equity | 1.32M | 1.29M | -299.07K | -810.60K | 41.34K | 459.10K |
Cash Flow | ||||||
| Free Cash Flow | -906.33K | -717.22K | -71.77K | -277.53K | -1.44M | -1.95M |
| Operating Cash Flow | -906.33K | -717.22K | -71.77K | -277.53K | -1.44M | -1.95M |
| Investing Cash Flow | -944.52K | 0.00 | 0.00 | 0.00 | 0.00 | 29.64K |
| Financing Cash Flow | 2.40M | 2.30M | 75.00K | 19.10K | 1.49M | 0.00 |
Restart Life Sciences Technical Analysis
Neutral
0.07
Price Trends
0.08
Negative
0.09
Negative
0.10
Negative
Market Momentum
>-0.01
Negative
51.23
Neutral
100.00
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:HEAL, the sentiment is Neutral. The current price of 0.07 is below the 20-day moving average (MA) of 0.07, below the 50-day MA of 0.08, and below the 200-day MA of 0.10, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 51.23 is Neutral, neither overbought nor oversold. The STOCH value of 100.00 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for TSE:HEAL.
Restart Life Sciences Peers Comparison
UnderperformOutperform
Sector (51)
TSE:HEAL
Restart Life Sciences
0.08
-0.02
-16.67%
TSE:MYND
MYND Life Sciences
0.07
0.00
0.00%
TSE:IBO
Universal Ibogaine Inc
0.01
-0.01
-50.00%
TSE:MBIO
Mindbio Therapeutics Corp.
0.24
-3.76
-94.00%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.